BAMCO Inc
ATRA icon

BAMCO Inc’s Atara Biotherapeutics ATRA Stock Holding History

BAMCO Inc’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,600
Closed -$24.1M – 315
2015
Q3 		$24.1M Buy
30,600
+30,320
+10,829% +$37M 0.11% 186
2015
Q2 		$369K Sell
280
-4,554
-94% -$5.22M ﹤0.01% 345
2015
Q1 		$5.02M Buy
+4,834
New +$3.19M 0.02% 269

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BAMCO Inc's ATRA Position: Q4 2015 in Review

BAMCO Inc sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 30,600 shares — an estimated $24.1M sold.

BAMCO Inc first reported a position in ATRA in Q1 2015 and held it in 3 quarters. The position peaked at $24.1M in Q3 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

  • BAMCO Inc reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • BAMCO Inc sold 30,600 Atara Biotherapeutics shares in Q4 2015, an estimated $24.1M.
  • BAMCO Inc first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 3 quarters.
  • BAMCO Inc's Atara Biotherapeutics position peaked at $24.1M in Q3 2015.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on BAMCO Inc's 13F filing for Q4 2015, filed 16 Feb 2016.